NCM
ALT icon

Nantahala Capital Management’s Altimmune ALT Stock Holding History

Nantahala Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,673
Closed -$10.4M – 56
2016
Q4 		$10.4M Hold
10,673
– – 1.08% 28
2016
Q3 		$9.29M Sell
10,673
-167
-2% -$131K 1.12% 26
2016
Q2 		$7.93M Buy
10,840
+1
+0% +$684 0.86% 28
2016
Q1 		$6.39M Sell
10,839
-459
-4% -$235K 0.66% 37
2015
Q4 		$6.44M Buy
11,298
+1,745
+18% +$870K 0.84% 36
2015
Q3 		$3.81M Buy
9,553
+1,180
+14% +$559K 0.52% 48
2015
Q2 		$4.52M Buy
8,373
+60
+0.7% +$30.3K 0.66% 49
2015
Q1 		$4.07M Buy
8,313
+585
+8% +$291K 0.68% 48
2014
Q4 		$4.2M Buy
7,728
+2,661
+53% +$1.37M 0.59% 48
2014
Q3 		$2.71M Buy
+5,067
New +$2.65M 0.33% 77

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Nantahala Capital Management's ALT Position: Q1 2017 in Review

Nantahala Capital Management sold out of Altimmune (ALT) in Q1 2017, closing a stake of 10,673 shares — an estimated $10.4M sold.

Nantahala Capital Management first reported a position in ALT in Q3 2014 and held it in 10 quarters. The position peaked at $10.4M in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

  • Nantahala Capital Management reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
  • Nantahala Capital Management sold 10,673 Altimmune shares in Q1 2017, an estimated $10.4M.
  • Nantahala Capital Management first reported a position in Altimmune in Q3 2014 and held it in 10 quarters.
  • Nantahala Capital Management's Altimmune position peaked at $10.4M in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on Nantahala Capital Management's 13F filing for Q1 2017, filed 15 May 2017.